cpi-818
corvus pharma
['cpi-818']
$crvs -29% new cpi-818 interim data presented at icml meeting new data supports cpi-818 potential to treat range of solid &amp; hematological cancers while pr stated positive data, market seems focused on one new patient that did not respond $crvs to meet w/ fda in q3 '23 to 
Catalyst Calendar, Big Mover stocks to watch, & model portfolios. Database & tools to help with your biotech stock research. not investment advice. https://t.co/5njnanqtbK